Welcome to our dedicated page for FendX Technologies news (Ticker: FDXTF), a resource for investors and traders seeking the latest updates and insights on FendX Technologies stock.
FendX Technologies Inc. develops surface-protection technologies designed to reduce the spread of harmful pathogens on everyday surfaces. Company updates center on its protective coatings portfolio, including REPELWRAP™ film, a liquid-based nano-coating technology, and a coated Foley catheter program being developed for antimicrobial use in medical-device settings.
Recurring news themes include patent activity for hygiene-related technologies, pilot-scale manufacturing work for liquid surface coatings, regulatory-pathway assessment for the catheter program, and business-development agreements involving antimicrobial formulations, manufacturing support, testing, branding, and commercialization planning.
FendX (OTCQB: FDXTF) entered an agreement dated April 28, 2026 with Innovotech to assess the U.S. FDA regulatory classification and pathway for its coated Foley catheter program. The engagement covers regulatory research and a recommended FDA pathway to support potential commercialization.
The company said next steps after pathway determination may include antimicrobial testing and possible further engagement of Innovotech to generate application-specific data to support development.
FendX (OTCQB: FDXTF) signed a statement of work with Galenvs on April 14, 2026 to begin pilot-scale manufacturing of its liquid surface coating, targeting scalable process development and quality benchmarking.
The project will produce three independent lots for internal evaluation and third-party testing. FendX noted prior provisional patent filing on October 21, 2025 and terminated a collaboration and MOU with Aquaox after a technical feasibility phase proved not feasible.
FendX (OTCQB: FDXTF) announced strategic shifts and development milestones on March 31, 2026, prioritizing a newly developed liquid surface coating with a provisional patent and discontinuing REPELWRAP film development.
The company filed provisional patents for a Foley catheter coating and an AI contamination detection app, entered a collaboration with Aquaox, completed share-for-debt settlements totaling $89,578 via issuance of 242,102 shares, and renewed IR services with a $28,080 fee reduction.
FendX (OTCQB: FDXTF) entered a collaboration agreement dated January 20, 2026 with Aquaox to formalize an initial feasibility phase following a November 18, 2025 MOU. The parties will assess technical feasibility and the ability to reliably formulate eco-friendly antimicrobial agents for potential product development.
Each party will bear its own costs, the agreement contains termination provisions, and advancement beyond feasibility depends on technical evaluation, regulatory considerations, and execution of additional agreements. There is no assurance the collaboration will lead to definitive deals, approvals, or commercial products.
FendX (OTCQB: FDXTF, CSE: FNDX, FSE: E8D0) announced extensions of two consulting agreements for branding and strategic marketing support. One agreement with a branding expert was extended to May 10, 2026 on the same monthly fee terms; the second consultant agreement was extended to June 15, 2026 on the same monthly fee terms. The company said it may renew either agreement for additional one‑month or multi‑month periods at its discretion.
The update discloses no changes to fees or material financial terms beyond the identical monthly fee arrangements and provides timeline clarity for near‑term consultant support through mid‑2026.
FendX (OTCQB: FDXTF) signed a Memorandum of Understanding dated November 17, 2025 with Aquaox to pursue development of advanced formulations of eco‑friendly pathogen‑eliminating agents for use in cleaning and disinfectant products across healthcare, consumer, and commercial markets.
The MOU contemplates a collaboration and supply relationship under a future Definitive Agreement, states Aquaox will oversee production equipment and supply, and says FendX will own any products and new intellectual property while Aquaox will own any new EPA certifications. The MOU term is 12 months and the Definitive Agreement is subject to due diligence and regulatory and corporate approvals, with no assurance it will be completed.
FendX (OTCQB: FDXTF) filed a provisional patent application with the US Patent and Trademark Office for an "Antimicrobial Coating for Long-Lasting Pathogen Control on High-Touch Surfaces" (application no. 63/936,328), filed August 7, 2025, with FendX as assignee.
The application, prepared by Drs. Carolyn Myers, Tohid Didar, Leyla Soleymani and Sara Moetakef Imani, describes a novel nanoparticle liquid coating engineered for easy application (roller or brush) to actively disrupt microbial contamination and provide sustained protection on high-touch surfaces. The company said it is assessing scale-up and distribution partnership opportunities to commercialize the technology.
FendX Technologies (OTCQB: FDXTF) announced that CEO Dr. Carolyn Myers has filed a provisional patent application for an AI-powered pathogen detection platform. The patent, titled "AI Adaptive App Pathogen Detection Platform," was filed on June 25, 2025, with the United States Patent and Trademark Office.
The technology combines mobile-based imaging, biosensor technology, and artificial intelligence to enable real-time pathogen detection on surfaces using smartphones. The innovation aims to create a portable diagnostic tool for both consumer and professional applications, moving beyond traditional lab-based testing methods.
FendX Technologies (OTCQB: FDXTF), a surface protection technology company, has announced a 10-for-1 share consolidation effective August 18, 2025. The consolidation will reduce the company's outstanding shares from 90,019,646 to approximately 9,001,965 shares.
The company's board approved this consolidation to optimize its share structure, potentially attract additional financing, and position FendX for growth. The stock will continue trading under the symbol "FNDX" with new CUSIP and ISIN numbers. Endeavor Trust Corporation will handle the administrative process of exchanging pre-consolidation shares for post-consolidation certificates.